TTC9B

Across TCGA pan-cancer cohorts, TTC9B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TTC9B data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TTC9B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC9B expression acts as an unfavorable survival marker.

LIHC, LUAD, and SKCM are the cancer types where TTC9B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
SKCM	OS	Median	All	0.301	0.786	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TTC9B–LIHC (DFS)

Open the LIHC breakdown →